Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
Live Nasdaq Composite: Markets Tank as Oil Soars on Mideast Fatigue
09:56am, Friday, 27'th Mar 2026
Live Updates Released: The Ultimate Guide To Retirement Income Most investors spend years learning how to pick good stocks and funds. Far fewer have a clear plan for turning those investments into a r
Stock Futures Rebuff President Trump's Deadline Extension
09:18am, Friday, 27'th Mar 2026
Stock futures are ending the week on a rough note, as oil prices move past President Donald Trump's deadline extension
AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
08:54am, Friday, 27'th Mar 2026
Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstru
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
07:00am, Friday, 27'th Mar 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduce
AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials
04:46am, Friday, 27'th Mar 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard on a subdued Friday session, after its experimental COPD treatment tozorak
AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials
04:41am, Friday, 27'th Mar 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard on a subdued Friday session,...
AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
03:51am, Friday, 27'th Mar 2026
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients' symptoms worsened, the company said.
AstraZeneca drug reduces COPD flare ups in late-stage trials
03:18am, Friday, 27'th Mar 2026
AstraZeneca said on Friday said its experimental treatment tozorakimab met the main goal in two late-stage trials and showed a meaningful reduction in flare ups of chr
Astrazeneca Plc (NYSE:AZN) Receives Average Rating of “Moderate Buy” from Analysts
02:50am, Thursday, 26'th Mar 2026
Shares of Astrazeneca Plc (NYSE: AZN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, MarketBeat reports. On
AstraZeneca (LON:AZN) Share Price Passes Above 200 Day Moving Average – What’s Next?
02:44am, Thursday, 26'th Mar 2026
AstraZeneca PLC (LON: AZN - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of £134.71 and traded as high as £140.
Advancements in Novel Immunotherapeutics in The Oncology Battle
10:30am, Tuesday, 24'th Mar 2026
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry
Gradient Investments LLC Has $16.96 Million Holdings in Astrazeneca Plc $AZN
06:28am, Monday, 23'rd Mar 2026
Gradient Investments LLC lifted its stake in shares of Astrazeneca Plc (NYSE: AZN) by 1,098.9% in the undefined quarter, according to the company in its most recent filing with the Securities and Exch
AstraZeneca PLC (LON:AZN) Receives £145.83 Average Target Price from Brokerages
01:12am, Saturday, 21'st Mar 2026
AstraZeneca PLC (LON: AZN - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, Marketbeat.com reports. One investme
First Look: FedEx beats, Wegovy HD cleared, Nexstar-Tegna closes
07:38am, Friday, 20'th Mar 2026
Stock News Supermicro co-founder charged over China diversions: Super Micro Computer (SMCI) co-founder YihâShyan âWallyâ Liaw and two others were indicted
AstraZeneca says it will build cell therapy base, innovation centre in Shanghai
12:52am, Thursday, 19'th Mar 2026
AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and innovation centre in Shanghai, aiming to become the first global drugmaker with end-to-
